OCALIVA® (obeticholic acid) is a prescription medicine used for the treatment of primary biliary cholangitis (PBC); its first approved treatment in nearly 20 years. Since this medicine is changing what's possible in PBC treatment, the brand had to encompass its revitalizing possibilities with a warm, energetic, and refreshing identity.
Our team worked on a range of design solutions for this brand, but my role included the development of the logo and identity as well as its accompanying print pieces.
Client: Intercept Pharmaceuticals • Agency: Cambridge BioMarketing
![](https://pro2-bar-s3-cdn-cf1.myportfolio.com/69e55c15906d238b05fdf75f431e3904/ce3d664affbfde2bf6d58beb4379ec2dd5199199708a03e7b60a29be03c4792014c30c16389fdad6_rw_1920.jpg?h=707c33cd545586d6bb65c38ce7d6487d)